logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Prevalence of mutant BRAF v600e in the papillary thyroid carcinoma in patients from Kazakhstan and its correlation with clinical-morphological tumor characteristic

[Surgery]
Askar Tlegenov; Zhangentkhan Abylaiuly; Dauren Adilbay; Shanar Yeleubaeva; Galym Adilbayev; Elvira Satbaeva; Svetlana Bolshakova;

The BRAFV600E mutation is the most frequent somatic oncogenic event in adult patients with papillary thyroid carcinoma (PTC). This work set out to determine the prevalence of mutant BRAF and its correlations with clinical-morphological characteristics of PTC, and to examine feasibility of detection of BRAFV600E in fine-needle aspiration biopsy material in patients from Kazakhstan. A total of 92 consequent patients diagnosed and treated for PTC from January 2016 to July 2017 were enrolled. Serial tissue sections of formalin-fixed paraffin embedded tissues were stained with hematoxylin and eosin, and immunohistochemically with monoclonal antibodies specific to the BRAFV600E protein. Positive immunohistochemical reaction was registered in 67.4 % of cases.

Download

References:
1. La Vecchia C., Malvezzi M., Bosetti C., Garavello W., Bertuccio P. [et al.] Thyroid cancer mortality and incidence: a global overview. Int. J. Cancer. 2015;136:2187-2195. https://doi.org/10.1002/ijc.29251
2. Grubbs E. G., Rich T. A., Li G., Sturgis E. M., Younes M. N. [et al.] Recent advances in thyroid cancer. Curr. Probl. Surg. 2008;45(3):156-250. https://doi.org/10.1067/j.cpsurg.2007.12.010
3. Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics 2010. CA Cancer J. Clin. 2010;60:277-300. https://doi.org/10.3322/caac.20073
4. Nishant A. R., Akbani B., Arman A., Adrian A., Harindra A. [et al.] Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Сell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050
5. Carol Li., Kathleen C., Lee E. B., SchneiderM. A., Zeiger A. BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: a meta-analysis. J. Clin. Endocrinol. Metab. 2012;97:4559– 4570. https://doi.org/10.1210/jc.2012-2104
6. Jeong D., Jeong Y., Park J. H., Han S. W., Kim S. Y. [et al.] BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann. Surg. Oncol. 2013;20:759-66. https://doi.org/10.1245/s10434-012-2494-0
7. Basolo F., Torregrossa L., Giannini R., Miccoli M., Lupi C. [et al.] Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 2010;95:4197-205. https://doi.org/10.1210/jc.2010-0337
8. Vasiliev E. V., Rumiantsev P. O., Saenko V. A., Ilyin A. A., Polyakova E. Yu. [et al.] Molecular analysis of structural disorders of the genome of papillary thyroid carcinoma. Molecular biology. 2004;38(4):642-653.
9. Yasuhiro I., Hiroshi Y., Minoru K., Kaoru K., Akihiro M. [et al.] BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients? World Journal of Surgery. 2014;38:679-687. https://doi.org/10.1007/s00268-013-2223-2
10. De Lellis R. A., Lloyd R., Heitz Ph. WHO Classification of tumors, Vol. 8, Pathology and genetics of tumors of the endocrine organs, 3rd ed. IARCPress, Lyon. 2004.
11. Yamashita S., Saenko V. A. Mechanisms of Disease: molecular genetics of childhood thyroid cancers. Nat. Clin. Pract. Endocrinol. Metab. 2007;3(5):422-429. https://doi.org/10.1038/ncpendmet0499
12. Ahmad O. B., Boschi-Pinto C., Lopez A. D., Murray Ch. J. L., Lozano R. [et al.] Age standardization of rates: a new WHO standard. GPE Discussion Paper Series: №31. EIP/GPE/EBD World Health Organization 2001. http://www.who.int/healthinfo/paper31.pdf
13. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-62. https://doi.org/10.1210/er.2007-0007
14. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer. 2005;12(2):245-62. https://doi.org/10.1677/erc.1.0978
15. Sargent R., Li Volsi V., Murphy J., Mantha G., Hunt J. L. BRAF mutation is unusual in chronic lymphocytic thyroiditis- associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr. Pathol. 2006;17(3):235-41.
16. Cibas E. S., Ali S. Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341- 1346. https://doi.org/10.1089/thy.2017.0500

Keywords: papillary thyroid carcinoma, BRAF mutation, tumor morphology, tumor aggressiveness, fine-needle aspiration biopsy


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy